Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ivermectin extended release - Lyndra

Drug Profile

Ivermectin extended release - Lyndra

Alternative Names: LYN-063; LYN-163

Latest Information Update: 24 Jun 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Lyndra
  • Class Antimalarials; Antineoplastics; Antiparasitics; Antivirals; Macrolides; Skin disorder therapies; Small molecules
  • Mechanism of Action Chloride channel agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Malaria

Most Recent Events

  • 09 Jun 2022 Phase-I clinical trials in Malaria (In volunteers, In adults) in Australia, USA (PO) (9360477; 700342576)
  • 22 Oct 2021 Ivermectin extended release is still in preclinical trials for Malaria in USA
  • 10 Sep 2021 Lyndra plans a phase I trial for Malaria (In volunteers, In adults) in Australia (PO, Controlled release) (ACTRN12621001218886)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top